Deck
Tenet Healthcare · THC · NYSE
Tenet runs 50 acute-care hospitals across eight states alongside USPI — a 533-center ambulatory surgery network (plus 26 surgical hospitals) — earning roughly equal profit dollars from a 16%-margin hospital chain and a 39%-margin physician-syndicated ASC platform.
$187
Price
$17B
Market cap
$21.3B
Revenue (TTM)
533
USPI surgery centers
plus 50 acute-care hospitals
From ~$65 in late-2002 (Medicare-billing scandal) to $3.60 in March 2009 on accounting/billing issues and high leverage; bottomed near $14 at COVID lows; reached a $244.80 intraday high in early March 2026, now $187.
2 · Two businesses, one ticker
Tenet trades like a hospital chain. Half its profit dollars come from a 40%-margin ASC platform that doesn't comp to one.
- The split. Hospital Operations is 76% of revenue at a 15.7% margin and earned $2.54B EBITDA in FY2025. USPI is 24% of revenue at a 39.2% margin and earned $2.03B — almost the same dollar contribution from a quarter of the top line.
- The peer mismatch. Surgery Partners (SGRY), the only listed pure-play ASC operator, prints 9.4× EV/EBITDA on a 17.7% margin. THC trades at 7.9× consolidated — alongside stressed acute-care peers UHS (5.3×) and CYH (5.5×). The consolidated multiple anchors on the hospital comp set.
- The math. Sum-of-parts at SGRY-comp multiples brackets equity at $19–27B against today's $17B market cap. Whether that gap closes depends on USPI sustaining 6%+ same-facility growth — the variable that resolves the bull-bear debate.
USPI has held a 21-percentage-point margin premium to SGRY for six straight years. That is the asset the consolidated multiple is missing.
3 · The cash-flow turnaround is the new fact
Free cash flow has 8×'d in three years. Tenet has retired $2.5B of stock and cut leverage from 6.4× to 2.25×.
$2.5B
FCF FY2025
from $321M in FY2022
16M
Net shares retired since FY2021
107M → 90M diluted
2.25×
Net debt / EBITDA
6.4× in 2017
21.4%
Adj. EBITDA margin
12.5% in 2018
USPI compounded at 7.5% same-facility revenue growth in 2025 while CEO Sutaria sold 14 lower-margin hospitals and locked in commercial rate escalators through 2027. FY2025 buybacks ran $1.39B — bigger than capex plus acquisitions combined. FY2026 guide assumes the cadence continues at $2.5–2.8B headline FCF, $1.6–1.83B after physician-JV distributions.
4 · The 2026–2027 policy gauntlet
Three federal rule changes hit the hospital book in sequence — and over half of Tenet's beds sit in the states most exposed.
- EPTC expiry — 2026. Enhanced ACA premium tax credits ended Dec 2025; the FY2026 guide already absorbs a $250M EBITDA hit on a ~20% exchange-enrollment decline. Q1 admissions fell only ~10% — better than feared, but H2 disenrollment is the real test.
- OBBBA Medicaid — 2027. State-directed payment caps and work requirements phase in from 2027. Bear-case estimates: $300–500M annual hospital EBITDA hit, none of it in current guidance. Tenet booked $1.34B of supplemental Medicaid in 2025 — the exposure window.
- Geographic concentration. Florida, South Carolina, Tennessee, and Texas hold over half of Tenet's licensed beds and never expanded Medicaid — the same states where EPTC enrollment falls hardest and where OBBBA caps bind first.
Sell-side has frozen FY2027 EPS at $17.76 — one cent above FY2026. The flat line says: 18 analysts can't size OBBBA yet.
5 · Three forensic flags worth tracking
Risk grade: Watch. The accounting is open about its own distortions, but two enforcement signals deserve real attention.
- The FY2024 'optics' problem. A $2.92B divestiture gain sits above the operating-income line in FY2024, lifting reported operating income from $3.0B normalized to $5.7B. Disclosed clearly, but every screen anchored on FY2024 GAAP overstates earnings power by 51%.
- SEC FOIA 7(A) exemption. A June 2025 short report cited an SEC FOIA response consistent with an active enforcement matter; the short alleges $675–845M of Medicare/Medicaid exposure. Resolution is binary, untimed, and independent of operating fundamentals.
- Accounting-officer transition + insider tape. Long-serving Principal Accounting Officer retires April 30, 2026; the LifePoint replacement starts May 1. CEO sold $15M of stock in September 2025; insiders bought zero shares in the trailing 12 months.
Long-term comp vests on adjusted EPS, FCF, and ROIC — the exact metrics the gain-on-sale presentation lifts. Not a fraud signal; an alignment one.
6 · Bull & Bear
Lean long, wait for confirmation. The SOTP gap and buyback flywheel are real, but two unresolved swing factors sit on the path.
- For. Sum-of-parts at ASC-comp multiples brackets equity at $19–27B vs. $17B market cap; sell-side $240 PT validates a portion of that range. Consensus FY2027 EPS frozen at $17.76 ignores buyback math — $1.4B annually retires 7–8% of the float.
- For. $2.5B FCF, 2.25× leverage, no maturities until late 2027 — a different balance sheet than the one that bottomed at $3.60 in 2009. Q1 2026 USPI same-facility revenue still grew 5.3% with the EPTC step-down already in the print.
- Against. USPI delivered 533 ASCs vs. its own 575–600 target — the M&A flywheel is slipping. Optum/SCA, owned by UnitedHealth, controls payer + physician + a competing 280-ASC platform and could steer commercial volume away starting 2026–2027.
- Against. The hospital book absorbs EPTC, OBBBA, and site-neutral Medicare reform on top of each other — over half of licensed beds sit where each rule cuts deepest. The SEC FOIA 7(A) matter and the May 1 PAO transition are independent risks unrelated to operating fundamentals.
My view — the bull substance carries more weight, but confirmation runs through Q3–Q4 2026 USPI prints. Two quarters of sub-5% same-facility growth would flip the call to avoid; sustained 6%+ would confirm the SOTP framing.
Watchlist to re-rate: USPI same-facility revenue growth in Q3 and Q4 2026 prints; SEC FOIA 7(A) resolution; H2 2026 OBBBA implementation rules and any state-directed payment carve-outs.